In vivo CAR T Expansion Vyriad is advancing in vivo CAR T and other cell therapies with Series B funding and clinical trial activity, signaling a strong opportunity to engage translational research partners, contract manufacturers, and immuno-oncology collaborators interested in rapid translation and democratized cell therapies.

Strategic Collaborations Active clinical research collaborations with Mayo Clinic and Regeneron indicate a track record of high-profile partnerships; target similar academic centers and biotech firms focused on virotherapy, gene delivery, and combination regimens to accelerate co-development opportunities.

Lead Asset VV169 Lead in vivo CAR T candidate VV169 and accompanying data position Vyriad for partnerships around late-stage development, manufacturing scale-up, and regulatory strategy; explore opportunities for joint development, licensing, or milestone-based deals.

Minnesota Footprint Strategic focus on Minnesota for trials and translation (G-Link) provides a regional access point for site networks, clinical trial services, and local industry partnerships; sales outreach can emphasize regional capabilities, cost efficiencies, and patient access programs.

Funding Momentum Recent multi-tranche Series B totaling eighty-five million and ongoing fundraising reflect healthy financial health and momentum; approach potential investors, strategic buyers, and CROs with a narrative of scalable programs, milestone-driven opportunities, and near-term clinical milestones.